Ndakotsu Andrew, Nduka Tagbo Charles, Agrawal Simran, Asuka Edinen
Department of Internal Medicine, MedStar Union Memorial Hospital Baltimore, Baltimore, MD, USA.
Department of Medicine, MedStar Health, Baltimore, MD, USA.
Heart Fail Rev. 2025 Mar 12. doi: 10.1007/s10741-025-10500-7.
Cirrhotic cardiomyopathy (CCM) is a cardiac dysfunction linked to chronic liver disease, primarily characterized by impaired cardiac response to stress, despite normal baseline function. It presents with both systolic and diastolic dysfunction, along with electrophysiological changes such as QT interval prolongation. CCM is driven by a combination of systemic inflammation, nitric oxide-induced vasodilation, and neurohormonal dysregulation, leading to myocardial impairment and abnormal vascular responses. Clinically, CCM often remains asymptomatic at rest, but patients may experience exercise intolerance or heart failure during stress. Diagnosis includes echocardiographic evaluation, biomarker analysis (NT-proBNP, troponins), and electrocardiography for detecting electrophysiologic abnormalities. Management is complicated by cirrhosis, limiting the use of conventional heart failure treatments, with liver transplantation being the most definitive intervention in severe cases. Early detection of CCM is vital, particularly for patients undergoing liver transplantation or major surgery, where cardiac complications can increase mortality. Further research is necessary to refine diagnostic criteria and treatment strategies.
肝硬化性心肌病(CCM)是一种与慢性肝病相关的心脏功能障碍,其主要特征是尽管基线功能正常,但心脏对应激的反应受损。它表现为收缩和舒张功能障碍,以及QT间期延长等电生理变化。CCM是由全身炎症、一氧化氮诱导的血管舒张和神经激素失调共同驱动的,导致心肌损伤和异常的血管反应。临床上,CCM在静息时通常无症状,但患者在应激时可能会出现运动不耐受或心力衰竭。诊断包括超声心动图评估、生物标志物分析(NT-proBNP、肌钙蛋白)以及用于检测电生理异常的心电图检查。由于肝硬化,管理变得复杂,限制了传统心力衰竭治疗方法的使用,肝移植是严重病例中最具决定性的干预措施。早期发现CCM至关重要,特别是对于接受肝移植或大手术的患者,因为心脏并发症会增加死亡率。需要进一步研究以完善诊断标准和治疗策略。